172 related articles for article (PubMed ID: 31679248)
1. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
[TBL] [Abstract][Full Text] [Related]
2. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need.
Patil TS; Deshpande AS; Deshpande S; Shende P
J Drug Target; 2019 Jan; 27(1):12-27. PubMed ID: 29561179
[TBL] [Abstract][Full Text] [Related]
3. Dry powder inhalers of antitubercular drugs.
Nainwal N; Sharma Y; Jakhmola V
Tuberculosis (Edinb); 2022 Jul; 135():102228. PubMed ID: 35779497
[TBL] [Abstract][Full Text] [Related]
4. Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future.
Mehta P; Bothiraja C; Kadam S; Pawar A
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S791-S806. PubMed ID: 30307321
[TBL] [Abstract][Full Text] [Related]
5. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
6. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
7. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
Srichana T; Eze FN; Thawithong E
Drug Dev Ind Pharm; 2022 Oct; 48(10):528-538. PubMed ID: 36214588
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
9. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
[TBL] [Abstract][Full Text] [Related]
10. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhalable formulations for anti-tubercular therapy.
Parumasivam T; Chang RY; Abdelghany S; Ye TT; Britton WJ; Chan HK
Adv Drug Deliv Rev; 2016 Jul; 102():83-101. PubMed ID: 27212477
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary drug delivery systems for tuberculosis treatment.
Pham DD; Fattal E; Tsapis N
Int J Pharm; 2015 Jan; 478(2):517-29. PubMed ID: 25499020
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical aerosols for the treatment and prevention of tuberculosis.
Hanif SN; Garcia-Contreras L
Front Cell Infect Microbiol; 2012; 2():118. PubMed ID: 22973562
[TBL] [Abstract][Full Text] [Related]
14. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
Machelart A; Salzano G; Li X; Demars A; Debrie AS; Menendez-Miranda M; Pancani E; Jouny S; Hoffmann E; Deboosere N; Belhaouane I; Rouanet C; Simar S; Talahari S; Giannini V; Villemagne B; Flipo M; Brosch R; Nesslany F; Deprez B; Muraille E; Locht C; Baulard AR; Willand N; Majlessi L; Gref R; Brodin P
ACS Nano; 2019 Apr; 13(4):3992-4007. PubMed ID: 30822386
[TBL] [Abstract][Full Text] [Related]
16. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
[TBL] [Abstract][Full Text] [Related]
17. How can nanoparticles contribute to antituberculosis therapy?
Costa-Gouveia J; Aínsa JA; Brodin P; Lucía A
Drug Discov Today; 2017 Mar; 22(3):600-607. PubMed ID: 28137645
[TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.
Stewart IE; Lukka PB; Liu J; Meibohm B; Gonzalez-Juarrero M; Braunstein MS; Lee RE; Hickey AJ
Pharm Res; 2019 Jul; 36(9):136. PubMed ID: 31321552
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
20. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
